Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Buttmann

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Frontiers in Neurology|July 14, 2022
OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in GermanyTjalf Ziemssen, Stephan Richter, Mathias Mäurer, et al.
Plos One|January 4, 2013
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosisThomas F Benkert, Lena Dietz, Elena M Hartmann, et al.
Brain : a Journal of Neurology|July 31, 2016
Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathyKathrin Doppler, Luise Appeltshauser, Carmen Villmann, et al.
Plos One|November 10, 2010
Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdownAxel Haarmann, Annika Deiss, Jürgen Prochaska, et al.
The Journal of Biological Chemistry|February 17, 2009
Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylaseArnab Nayak, Judith Glöckner-Pagel, Martin Vaeth, et al.
Frontiers in Neurology|May 26, 2022
Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE StudyMartin S Weber, Mathias Buttmann, Sven G Meuth, et al.
Cancer Research|October 15, 2009
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cellsFlorian Reim, Yvonne Dombrowski, Cathrin Ritter, et al.
Acta Neuropathologica|March 28, 2015
Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signallingAxel Haarmann, Eva Nowak, Annika Deiß, et al.
Human Molecular Genetics|February 8, 2017
Pathogenic inflammation in the CNS of mice carrying human PLP1 mutationsJanos Groh, Hana C Friedman, Nadiya Orel, et al.
Brain, Behavior, and Immunity|April 14, 2010
Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesisClaudia Heidbrink, Sebastian F M Häusler, Mathias Buttmann, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Frontiers in Neurology|July 14, 2022
OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in GermanyTjalf Ziemssen, Stephan Richter, Mathias Mäurer, et al.
Plos One|January 4, 2013
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosisThomas F Benkert, Lena Dietz, Elena M Hartmann, et al.
Brain : a Journal of Neurology|July 31, 2016
Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathyKathrin Doppler, Luise Appeltshauser, Carmen Villmann, et al.
Plos One|November 10, 2010
Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdownAxel Haarmann, Annika Deiss, Jürgen Prochaska, et al.
The Journal of Biological Chemistry|February 17, 2009
Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylaseArnab Nayak, Judith Glöckner-Pagel, Martin Vaeth, et al.
Frontiers in Neurology|May 26, 2022
Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE StudyMartin S Weber, Mathias Buttmann, Sven G Meuth, et al.
Cancer Research|October 15, 2009
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cellsFlorian Reim, Yvonne Dombrowski, Cathrin Ritter, et al.
Acta Neuropathologica|March 28, 2015
Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signallingAxel Haarmann, Eva Nowak, Annika Deiß, et al.
Human Molecular Genetics|February 8, 2017
Pathogenic inflammation in the CNS of mice carrying human PLP1 mutationsJanos Groh, Hana C Friedman, Nadiya Orel, et al.
Brain, Behavior, and Immunity|April 14, 2010
Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesisClaudia Heidbrink, Sebastian F M Häusler, Mathias Buttmann, et al.
Pageof 6